{"DataElement":{"publicId":"6459381","version":"1","preferredName":"Patient Chronic Hepatitis B Virus Infectious Disorder Receiving Suppressive Antiviral Therapy Undetectable Viral Load Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The coded indicator to determine trial eligibility for questions related to chronic HBV infection and undetectable viral loads when taking suppressive therapy as outlined in the study protocol.","longName":"HBV_SUPRSV_TX_UNDET_VL","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"6459375","version":"1","preferredName":"Patient Chronic Hepatitis B Virus Infectious Disorder Receive Suppressive Antiviral Therapy Undetectable Viral Load Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Usually used to describe a condition that is persistent and long standing._Hepatitis B Virus (HBV) is the prototype of the Hepadnavirus Family.  Included in the family are the Woodchuck Hepatitis Virus (WHV) and the Duck Hepatitis B Virus (DHBV) which provide animal models of infection.  The HBV genome is a partially double stranded circular DNA.  A viral reverse transcriptase is bound to the 5' extremity of the long strand._A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact._To take, accept, or get something offered._Ongoing antiviral therapy to reduce the frequency of recurrence or prevent transmission._The inability to be noticed, identified or discovered._The number of viral particles (usually HIV) in a sample of blood plasma._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2233604v1.0:6459373v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6459373","version":"1","preferredName":"Chronic Hepatitis B Virus Infectious Disorder Receive Suppressive Antiviral Therapy Undetectable Viral Load Clinical Trial Eligibility Criteria","preferredDefinition":"Usually used to describe a condition that is persistent and long standing.:Hepatitis B Virus (HBV) is the prototype of the Hepadnavirus Family.  Included in the family are the Woodchuck Hepatitis Virus (WHV) and the Duck Hepatitis B Virus (DHBV) which provide animal models of infection.  The HBV genome is a partially double stranded circular DNA.  A viral reverse transcriptase is bound to the 5' extremity of the long strand.:A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.:To take, accept, or get something offered.:Ongoing antiviral therapy to reduce the frequency of recurrence or prevent transmission.:The inability to be noticed, identified or discovered.:The number of viral particles (usually HIV) in a sample of blood plasma.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"6459373v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic","conceptCode":"C14141","definition":"Usually used to describe a condition that is persistent and long standing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Hepatitis B Virus","conceptCode":"C14215","definition":"Hepatitis B Virus (HBV) is the prototype of the Hepadnavirus Family.  Included in the family are the Woodchuck Hepatitis Virus (WHV) and the Duck Hepatitis B Virus (DHBV) which provide animal models of infection.  The HBV genome is a partially double stranded circular DNA.  A viral reverse transcriptase is bound to the 5' extremity of the long strand.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Infectious Disorder","conceptCode":"C26726","definition":"A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Suppressive Antiviral Therapy","conceptCode":"C155924","definition":"Ongoing antiviral therapy to reduce the frequency of recurrence or prevent transmission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Undetectable","conceptCode":"C111568","definition":"The inability to be noticed, identified or discovered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Viral Load","conceptCode":"C51952","definition":"The number of viral particles (usually HIV) in a sample of blood plasma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"775690E5-5E96-4D14-E053-F662850A1A63","latestVersionIndicator":"Yes","beginDate":"2018-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-03","modifiedBy":"ONEDATA","dateModified":"2018-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"775690E5-5EA7-4D14-E053-F662850A1A63","latestVersionIndicator":"Yes","beginDate":"2018-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-03","modifiedBy":"TAYLORT","dateModified":"2018-11-01","changeDescription":"11/1/18 TMT released. 10-3-18 tmt/10200.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876422","version":"1","longName":"Disease Status & Genetics","context":"Theradex"}]}],"AlternateNames":[{"name":"NRG","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"If patient has evidence of ch","type":"Preferred Question Text","description":"If patient has evidence of chronic Hepatitis B virus (HBV) infection, is HBV viral load undetectable on suppressive therapy (if indicated)?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Has patient been screened for HBV up to 28 days prior to study drug using standard virus lab panel, positive for HBsAg and/or HBcAb will be eligible if they are negative for HBV DNA and receiving prophylactic antiviral therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"If patient is Hepatitis B positive and circulating virus is not detected, has prophylactic HBV therapy been recommended?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"If patient has known chronic hepatitis B virus (HBV) infection, is viral load undetectable on suppressive therapy if indicated?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"If patient has evidence of chronic Hepatitis B virus (HBV) infection, is HBV viral load undetectable on suppressive therapy (with no medications prohibited by this protocol [e.g. drug-drug interactions]), if indicated?","url":null,"context":"Theradex"},{"name":"CRF TEXT 1","type":"Alternate Question Text","description":"If yes, was the HBV viral load undetectable within 28 days prior to step 2 registration?","url":null,"context":"NRG"},{"name":"NRG CRF_Text 1","type":"Alternate Question Text","description":"If the patient has a history of hepatitis B infection, does the patient have undetectable viral load?","url":null,"context":"NRG"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"If there is evidence of chronic Hepatitis B virus (HBV) infection, is HBV viral load undetectable on suppressive therapy (if indicated), values not conforming to this may be enrolled at the treating physician's discretion?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"If patient has evidence of chronic Hepatitis B virus (HBV) infection, is HBV viral load undetectable on suppressive therapy (if indicated, provided there is no expected drug-drug interaction)?","url":null,"context":"Theradex"},{"name":"NRG CRF_Text 2","type":"Alternate Question Text","description":"If yes, was the HBV viral load undetectable at enrollment?","url":null,"context":"NRG"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"If patient has evidence of chronic Hepatitis B virus (HBV) infection, is HBV viral load undetectable on suppressive therapy that does not interact with study therapy, if indicated?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"If patient has evidence of chronic Hepatitis B virus (HBV) infection, is HBV viral load undetectable on suppressive therapy (e.g., not HBsAg reactive), if indicated?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"If patient has evidence of chronic Hepatitis B virus (HBV) infection, is HBV viral load undetectable on suppressive therapy (if indicated)?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"If the patient has evidence of chronic Hepatitis B virus (HBV) infection, is HBV viral load undetectable on suppressive therapy (if indicated)?","url":null,"context":"Theradex"},{"name":"NRG_CRF_TEXT3","type":"Alternate Question Text","description":"For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.","url":null,"context":"NRG"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"If patient has chronic Hepatitis B virus (HBV) infection, is HBV viral load undetectable on suppressive therapy (if indicated)?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"If patient has a known history of chronic hepatitis B virus (HBV) infection, is the HBV viral load undectable on suppressive therapy, if indicated?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"If there is evidence of chronic Hepatitis B virus (HBV) infection, is HBV viral load undetectable on suppressive therapy (if indicated)?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"If there is evidence of chronic Hepatitis B virus (HBV) infection, is the HBV load undetectable on suppressive therapy (if indicated)?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"If patient has evidence of chronic Hepatitis B virus (HBV) infection, is the HBV viral load undetectable on suppressive therapy (if indicated)?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"If patient has evidence of chronic hepatitis B virus (HBV) infection, are they currently on treatment and have an undetectable HBV viral load?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"If patient with HBV infection will be included, does patient meet all the following criteria: 1. Demonstrated absence of HCV co-infection or history of HCV co-infection (Note that the sponsorâ€™s 3.1.11 is more lenient because it allows for history of HBC), 2. Demonstrated absence of HIV infection, 3. Participants with active HBV infection are eligible if they are Receiving anti-viral treatment for at least 6 weeks prior to study treatment, HBV DNA is suppressed to less than 100 IU/mL and transaminase levels are below ULN?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"If patient has evidence of chronic Hepatitis B virus (HBV) infection, is HBV viral load undetectable on suppressive therapy within 28 days of enrollment (if indicated)?","url":null,"context":"Theradex"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"775690E5-5ECA-4D14-E053-F662850A1A63","latestVersionIndicator":"Yes","beginDate":"2018-10-03","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-03","modifiedBy":"SOKKERL","dateModified":"2023-10-17","changeDescription":"11/1/18 TMT released. 10-3-18 tmt/10200.","administrativeNotes":"2023.5.3 AQT added per ticket request CADSR0002390. ak 8/2/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"}}